1)Takagi Y, Nakajima T, Shimazaki A et al:Pharmacological characteristics of AFP-168(tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78:767-776, 2004
2)桑山泰明,米虫節夫,タフルプロスト共同試験グループ:正常眼圧緑内障を対象とした0.0015%タフルプロストの眼圧下降効果に関するプラセボを対照とした多施設共同無作為化二重盲検第Ⅲ相臨床試験.日眼会誌 114:436-443,2010
3)中野聡子,久保田敏昭:ラタノプロストからタフルプロストへの切り替えによる長期効果.あたらしい眼科 27:1727-1730,2010
4)Mayama C, Ishii K, Saeki T et al:Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest Ophthalmol Vis Sci 51:4117-4124, 2010
5)Kurashima H, Watabe H, Sato N et al:Effects of prostaglandin F2α analogues on endothelin-1-induced impairment of rabbit ocular blood flow:comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res 91:853-859, 2010
6)Tsuda S, Yokoyama Y, Chiba N et al:Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type. J Glaucoma 22:398-403, 2013
7)杉山哲也・柴田真帆・小嶌祥太・他:タフルプロスト点眼による原発開放隅角緑内障眼の視神経乳頭血流変化.臨床眼科 65:475-479,2011
8)八百枝潔・白柏基宏・田中隆之・他:緑内障眼のラタノプロスト点眼からタフルプロスト点眼への切替えによる乳頭血流変化.臨眼 65:319-323,2011
9)大黒幾代・鶴田みどり・片井麻貴・他:正常眼圧緑内障におけるタフルプロストの視神経乳頭血流への影響.眼科 52:1921-1926,2010
10)Sugiyama T, Araie M, Riva CE et al:Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol 88:723-729, 2010
11)Anderson DR, Patella VM:Automated Static Perimetry. 2nd ed. pp121-190. Mosby, St Louis, 1999
を用いた視神経乳頭辺縁部組織血流の領域別評価.あたらしい眼科 27:1279-1285,2010
13)Dong Y, Watabe H, Su G et al:Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res 87:251-256, 2008
14)Fukano Y, Kawazu K:Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos 37:1622-1634, 2009
15)Sugiyama T, Kojima S, Ishida O et al:Changes in optic nerve head blood flow induced by the combined therapy of latanoprost and beta blockers. Acta Ophthalmol 87:797-800, 2009
16)Inoue K, Tanaka A, Tomita G:Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol 7:1411-1416, 2013
17)Pillunat LE, Lang GK, Harris A:The visual response to increased ocular blood flow in normal pressure glaucoma. Surv Ophthalmol 38(Suppl):S139-147, 1994
18)Yamada M, Ohkubo S, Higashide T et al:Differentiation by imaging of superior segmental optic hypoplasia and normal-tension glaucoma with inferior visual field defects only. Jpn J Ophthalmol 57:25-33, 2013
19)Klamann MK, Grünert A, Maier AK et al:Comparison of functional and morphological diagnostics in glaucoma patients and healthy subjects. Ophthalmic Res 49:192-198, 2013
20)Kanamori A, Naka M, Fukuda M et al:Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 247:1353-1360, 2009
21)Tsuda S, Yokoyama Y, Chiba N et al:Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type. J Glaucoma 22:398-403, 2013
22)Javitt JC:When does the failure to find a difference mean that there is none? Arch Ophthalmol 107:1034-1040, 1989